# Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid

> **NCT05578820** · PHASE1 · COMPLETED · sponsor: **Gene Surgery LLC** · enrollment: 21 (actual)

## Conditions studied

- Sarcoma
- Melanoma
- Squamous Cell Carcinoma of Head and Neck
- Breast Neoplasms
- Uterine Cervical Neoplasms
- Vulvar Neoplasms
- Penile Neoplasms
- Anus Neoplasms

## Interventions

- **BIOLOGICAL:** Stimotimagene copolymerplasmid
- **DRUG:** Ganciclovir

## Key facts

- **NCT ID:** NCT05578820
- **Lead sponsor:** Gene Surgery LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-01
- **Primary completion:** 2024-04-11
- **Final completion:** 2024-04-11
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2024-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05578820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05578820, "Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT05578820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*